Fourteen cases of gynecomastia occurring during highly active antiretroviral therapy (HAART) have been reported in the literature. To date, no specific therapeutic approach has been proposed, and gynecomastia has usually persisted. We report 4 new cases of HAART-induced gynecomastia that were successfully treated with percutaneous dihydrotestosterone gel.
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Fourteen cases of gynecomastia occurring during highly active antiretroviral therapy (HAART) have been reported in the literature. To date, no specific therapeutic approach has been proposed, and gynecomastia has usually persisted. We report 4 new cases of HAART-induced gynecomastia that were successfully treated with percutaneous dihydrotestosterone gel.
Fourteen cases of gynecomastia (GM) [1] [2] [3] [4] [5] [6] and 2 cases of breast hypertrophy in women [7, 8] occurring during highly active antiretroviral therapy (HAART) have been reported in the literature. For only 4 patients did GM resolve at some unspecified time or at 1, 5, or 7 months after changing the HAART regimen (table 1) . For the 12 remaining patients, both men and women, breast hypertrophy persisted for many months and may have been responsible for one suicide [2] .
Dihydrotestosterone (DHT; Andractim [Besins-Iscovesco]) is a natural metabolite of testosterone that has antiestrogen activity and cannot be converted into estradiol at the tissue level. Systemic [9] or locally [10] administered DHT has been successfully prescribed for the treatment of patiens with idiopathic and estrogen-induced GM. We report 4 new cases of GM occurring during HAART for which percutaneous DHT (androstanolone) gel application led to dramatic regression of breast enlargement. 3 and his HIV load was !200 copies/mL. Prolactin, D4-androstenedione, and total testosterone levels were within normal ranges. In January 1999, he began local application of DHT gel to his breasts. Within 15 days, GM disappeared. He stopped DHT therapy 15 days later and has had no relapse to date. 3 and his HIV load was !200 copies/ mL. Prolactin, D4-androstenedione, and total testosterone levels were within normal ranges. In July 2000, he started local application of DHT gel to the breasts. Within 10 days, pain disappeared and GM regressed. GM finally disappeared after 30 days. He stopped the treatment 30 days later and has had no relapse to date.
Discussion. Two mechanisms might explain the occurrence of breast enlargement among patients who are receiving HAART: (1) pseudo-GM, in which the enlargement is due to an increase of adipose tissue, and (2) real GM with glandular hypertrophy. Fat accumulation is a well-known phenomenon for patients receiving HAART that includes a protease inhibitor. Stavudine has also been reported to induce GM [6] , but it is better known to cause fat atrophy [11] . Eight of the 18 men (table 1) had lipodystrophy with mostly fat accumulation, but true GM with glandular structures was confirmed by mammography, ultrasonography, or both for 8 of the 18 men (table 1). These findings prompted us to think that breast enlargement would be due to drugs having a mammotropic action, rather than to fat accumulation in the breasts. On the basis of our analysis of both the literature and our patients (table 1), no particular class of molecule included in HAART seems to be a particularly good candidate to explain this effect.
The mammotropic action of drugs can be divided into 2 main known types: those that mimic estrogen or progesterone at peripheral receptor sites (e.g., digitalis or spironolactone) and those that increase secretion of prolactin (e.g., phenothiazine derivatives or tricyclic antidepressants). The latter drugs cause breast hypertrophy in men and women in equal proportions, and in women, they also induce galactorrhea and amenorrhea. The 2 women [6, 7] exhibited neither these symptoms nor high prolactin levels, as did 13 of the 18 men (table  1) . For the remaining 2 men with abnormally high prolactin levels, GM might have been caused by the neuroleptic therapy they received concomitantly (table 1) .
More likely, the mechanism involved for HAART would be the mimicking of the effect of estrogen on breast tissue. In fact, drugs that use this mechanism fairly frequently cause GM in men, as for HAART. However, women rarely note or complain of breast enlargement, especially because none of these agents has ever been reported to induce lactation. Furthermore, the dramatic effect of DHT gel, which has an antiestrogen effect, reinforces this last hypothesis.
This hypothesis should be tested on a larger cohort of patients (e.g., in a controlled clinical trial); however, from a practical point of view, when such GM is observed in patients who are receiving HAART and when a careful search has been done to detect predisposing causes that should be specifically treated, rapid, beneficial symptomatic response can be obtained with local application of DHT gel, 5 g/day given once daily for 1-3 months. This simple treatment seems to be particularly well tolerated: no side effects have been reported in the literature [10] or were observed among the patients who we studied. Nevertheless, the anecdotal nature of the effect of DHT presented here prompts us to think that other systemic androgenic therapies (e.g., testosterone gel) might have the same effect.
